{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:24:21Z","timestamp":1791645861328,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T00:00:00Z","timestamp":1381881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10384-013-0283-3","type":"journal-article","created":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T05:34:22Z","timestamp":1381815262000},"page":"75-80","source":"Crossref","is-referenced-by-count":20,"title":["Clinical course of patients with Beh\u00e7et\u2019s uveitis following discontinuation of infliximab therapy"],"prefix":"10.1007","volume":"58","author":[{"given":"Tatsushi","family":"Kawaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koju","family":"Kamoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Miyanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,16]]},"reference":[{"key":"283_CR1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. N Engl J Med. 1999;341:1284\u201391.","journal-title":"N Engl J Med."},{"key":"283_CR2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/08830189709116845","volume":"14","author":"RB Nussenblatt","year":"1997","unstructured":"Nussenblatt RB. Uveitis in Beh\u00e7et\u2019s disease. Int Rev Immunol. 1997;14:67\u201379.","journal-title":"Int Rev Immunol."},{"key":"283_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0039-6257(97)00026-X","volume":"42","author":"RK George","year":"1997","unstructured":"George RK, Chan CC, Whitcup SM, Nussenblatt RB. Ocular immunopathology of Beh\u00e7et\u2019s disease. Surv Ophthalmol. 1997;42:157\u201362.","journal-title":"Surv Ophthalmol."},{"key":"283_CR4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00417-005-0005-8","volume":"243","author":"M Takeuchi","year":"2005","unstructured":"Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, et al. Risk and prognostic factors of poor visual outcome in Beh\u00e7et\u2019s disease. Graefe\u2019s Arch Clin Exp Ophthalmol. 2005;243:1147\u201352.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol."},{"key":"283_CR5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/08830189709116844","volume":"14","author":"M Mochizuki","year":"1997","unstructured":"Mochizuki M. Immunotherapy for Beh\u00e7et\u2019s disease. Int Rev Immunol. 1997;14:49\u201366.","journal-title":"Int Rev Immunol."},{"key":"283_CR6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Beh\u00e7et\u2019s disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373\u201380.","journal-title":"Am J Ophthalmol."},{"key":"283_CR7","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20138.","journal-title":"J Rheumatol."},{"key":"283_CR8","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum. 2005;52:2478\u201384.","journal-title":"Arthritis Rheum."},{"key":"283_CR9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","volume":"26","author":"AM Abu El-Asrar","year":"2005","unstructured":"Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease. Int Ophthalmol. 2005;26:83\u201392.","journal-title":"Int Ophthalmol."},{"key":"283_CR10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10384-006-0425-y","volume":"51","author":"M Accorinti","year":"2007","unstructured":"Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol. 2007;51:53\u20137.","journal-title":"Jpn J Ophthalmol."},{"key":"283_CR11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Beh\u00e7et\u2019s disease. Br J Ophthalmol. 2010;94:284\u20138.","journal-title":"Br J Ophthalmol."},{"key":"283_CR12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/jop.2010.0031","volume":"26","author":"T Kawaguchi","year":"2010","unstructured":"Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M. Regression of optic disc neovascularization in patients with Beh\u00e7et\u2019s uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther. 2010;26:627\u201330.","journal-title":"J Ocul Pharmacol Ther."},{"key":"283_CR13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/bjo.2010.194464","volume":"95","author":"H Keino","year":"2011","unstructured":"Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Beh\u00e7et\u2019s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245\u201350.","journal-title":"Br J Ophthalmol."},{"key":"283_CR14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Mochizuki M. Ocular Beh\u00e7et\u2019s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease. Arch Ophthalmol. 2012;130:592\u20138.","journal-title":"Arch Ophthalmol."},{"key":"283_CR15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10384-012-0182-z","volume":"56","author":"A Yoshida","year":"2012","unstructured":"Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol. 2012;56:536\u201343.","journal-title":"Jpn J Ophthalmol."},{"key":"283_CR16","first-page":"924","volume":"35","author":"SR Plank","year":"1994","unstructured":"Plank SR, Huang XN, Robertson JE, Rosenbaum JT. Cytokine mRNA in rat tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci. 1994;35:924\u201330.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"283_CR17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-4835(95)80011-5","volume":"60","author":"AF Vos De","year":"1995","unstructured":"De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Tumour necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res. 1995;60:199\u2013207.","journal-title":"Exp Eye Res."},{"key":"283_CR18","first-page":"2211","volume":"37","author":"G Sartani","year":"1996","unstructured":"Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211\u20138.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"5 Suppl 24","key":"283_CR19","first-page":"S6","volume":"19","author":"A G\u00fcl","year":"2001","unstructured":"G\u00fcl A. Beh\u00e7et\u2019s disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S6\u201312.","journal-title":"Clin Exp Rheumatol."},{"key":"283_CR20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","volume":"142","author":"JK Ahn","year":"2006","unstructured":"Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Beh\u00e7et uveitis. Am J Ophthalmol. 2006;142:429\u201334.","journal-title":"Am J Ophthalmol."},{"key":"283_CR21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098\u2013104.","journal-title":"N Engl J Med."},{"key":"283_CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/41.2.231","volume":"41","author":"P Rovere Querini","year":"2002","unstructured":"Rovere Querini P, Vecellio M, Sabbadini MG, Ciboddo G. Miliary tuberculosis after biological therapy for rheumatoid arthritis. Rheumatology (Oxford). 2002;41:231.","journal-title":"Rheumatology (Oxford)."},{"key":"283_CR23","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","volume":"52","author":"J Listing","year":"2005","unstructured":"Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403\u201312.","journal-title":"Arthritis Rheum."},{"key":"283_CR24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","volume":"344","author":"A Warris","year":"2001","unstructured":"Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099\u2013100.","journal-title":"N Engl J Med."},{"key":"283_CR25","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/art.10374","volume":"46","author":"T Gl\u00fcck","year":"2002","unstructured":"Gl\u00fcck T, Linde HJ, Sch\u00f6lmerich J, M\u00fcller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002;46:2255\u20137.","journal-title":"Arthritis Rheum."},{"key":"283_CR26","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M Bandt De","year":"2005","unstructured":"De Bandt M, Sibilia J, Le Lo\u00ebt X, Prouzeau S, Fautrel B, Marcelli C, et al. Club rhumatismes et inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545\u201351.","journal-title":"Arthritis Res Ther."},{"key":"283_CR27","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513\u20138.","journal-title":"Arthritis Rheum."},{"key":"283_CR28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10384-012-0198-4","volume":"57","author":"Y Kawazoe","year":"2013","unstructured":"Kawazoe Y, Sugita S, Yamada Y, Akino A, Miura K, Mochizuki M. Psoriasis triggered by infliximab in a patient with Beh\u00e7et\u2019s disease. Jpn J Ophthalmol. 2013;57:95\u20137.","journal-title":"Jpn J Ophthalmol."},{"key":"283_CR29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","volume":"98","author":"A Cheifetz","year":"2003","unstructured":"Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315\u201324.","journal-title":"Am J Gastroenterol."},{"key":"283_CR30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903\u201312.","journal-title":"Arch Ophthalmol."},{"key":"283_CR31","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M, Chindamo D, Cassar\u00e0 E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et\u2019s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"283_CR32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10792-010-9372-1","volume":"30","author":"A Ad\u00e1n","year":"2010","unstructured":"Ad\u00e1n A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Beh\u00e7et\u2019s disease after withdrawal of infusions. Int Ophthalmol. 2010;30:577\u201381.","journal-title":"Int Ophthalmol."},{"key":"283_CR33","first-page":"291","volume":"18","author":"Beh\u00e7et\u2019s disease research committee of Japan","year":"1974","unstructured":"Beh\u00e7et\u2019s disease research committee of Japan. Beh\u00e7et\u2019s disease: guide to diagnosis of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol. 1974;18:291\u20134.","journal-title":"Jpn J Ophthalmol."},{"key":"283_CR34","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3748\/wjg.v13.i39.5238","volume":"13","author":"R Caviglia","year":"2007","unstructured":"Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata M, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol. 2007;13:5238\u201344.","journal-title":"World J Gastroenterol."},{"key":"283_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O\u2019Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27\u201335.","journal-title":"Arthritis Rheum."},{"key":"283_CR36","unstructured":"Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol. 2006; 24(6 Suppl 43): S-33-6."},{"key":"283_CR37","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3\u00a0years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7:R439\u201344.","journal-title":"Arthritis Res Ther."},{"key":"283_CR38","first-page":"510","volume":"34","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, et al. Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol. 2007;34:510\u20135.","journal-title":"J Rheumatol."},{"key":"283_CR39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1167\/iovs.10-5916","volume":"52","author":"S Sugita","year":"2011","unstructured":"Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M. Induction of regulatory T cells by infliximab in Beh\u00e7et\u2019s disease. Invest Ophthalmol Vis Sci. 2011;52:476\u201384.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"283_CR40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","volume":"204","author":"S Nadkarni","year":"2007","unstructured":"Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-\u03b1 therapy induces a distinct regulatory T-cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204:33\u20139.","journal-title":"J Exp Med."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-013-0283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-013-0283-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-013-0283-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T12:20:38Z","timestamp":1559132438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-013-0283-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,16]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1007\/s10384-013-0283-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,16]]}}}